<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04727671</url>
  </required_header>
  <id_info>
    <org_study_id>Ph-CT-4298</org_study_id>
    <nct_id>NCT04727671</nct_id>
  </id_info>
  <brief_title>Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.</brief_title>
  <official_title>Effect of GnRH Agonist (Long Protocol) vs GnRH Antagonist (Flexible Protocol) on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damascus University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damascus University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, non-randomised, open-label, clinical trial is conducting on polycystic&#xD;
      ovary syndrome (PCOS) subjects to compare the effects of two pituitary suppression regimens;&#xD;
      GnRH Agonist-Long Protocol and GnRH Antagonist-Flexible Protocol on clinical and&#xD;
      embryological IVF/ICSI outcomes, and on the follicular fluid levels of Placental Growth&#xD;
      Factor (PlGF); which is known for his pivotal role in the regulation of ovulation, embryo&#xD;
      development, and implantation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Follicular fluid Placental Growth Factor (PlGF) Concentrations:</measure>
    <time_frame>Immediately after oocyte retrieval (35±2 hours after hCG administration)</time_frame>
    <description>Follicular fluid samples will be obtained on the day of oocyte retrieval, then they will be centrifuged to eliminate cellular elements and debris. After that, the supernatants will be frozen at -80 until assayed using an Elisa kit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes retrieved</measure>
    <time_frame>Immediately after oocyte retrieval (35±2 hours after hCG administration)</time_frame>
    <description>The oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration 35±2 hours after hCG administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Metaphase II Oocytes (MII):</measure>
    <time_frame>Within two hours after oocyte retrieval</time_frame>
    <description>The oocyte maturity will be assessed using Nikon SMZ1500 stereoscope.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maturation Rate%:</measure>
    <time_frame>Within two hours after oocyte retrieval</time_frame>
    <description>Maturation Rate is calculated by dividing the number of mature (MII) oocytes by the number of retrieved oocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization Rate%:</measure>
    <time_frame>16-18 hours after microinjection.</time_frame>
    <description>Fertilization Rate is calculated by dividing the number of obtained zygote (2PN) by the number of injected oocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cleavage Rate%:</measure>
    <time_frame>Day 2 after microinjection.</time_frame>
    <description>Cleavage rate is calculated by dividing the number of cleavaged embryos by the number of zygotes (2PN).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo Quality:</measure>
    <time_frame>Day of transfer (2 or 3 days after microinjection).</time_frame>
    <description>Embryos are assessed using Nikon SMZ1500 stereoscope based on ESHRE criteria (2011).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Quality Embryos rate%:</measure>
    <time_frame>Day of transfer (2 or 3 days after microinjection).</time_frame>
    <description>High Quality Embryos rate is calculated by dividing the number of high quality embryos (Grade I) by the total number of cleavaged embryos.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Pregnancy Rate% (Per Embryo Transfer):</measure>
    <time_frame>2 weeks after embryo transfer</time_frame>
    <description>Biochemical pregnancy is defined as a positive serum beta-hCG pregnancy test after 2 weeks of embryo transfer. The biochemical pregnancy rate is calculated by dividing the number of women who are biochemically pregnant by the number of women who have at least 1 embryo transferred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pregnancy Rate% (Per Embryo Transfer):</measure>
    <time_frame>3-4 weeks after embryo transfer</time_frame>
    <description>Clinical pregnancy is defined as the presence of a gestational sac on ultrasound after 3-4 weeks of embryo transfer. The clinical pregnancy rate is calculated as by dividing the number of women who are clinically pregnant divided by the number of women who have at least 1 embryo transferred.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>In Vitro Fertilization</condition>
  <condition>Intracytoplasmic Sperm Injection</condition>
  <condition>Infertility</condition>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Agonist Group (Long protocol):</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The pituitary down-regulation in this group will be carried out using 0.05-0.1 mg of Triptorelin acetate subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the menstrual cycle until the ovulation triggering day. When the suppressive effect is obtained, ovarian stimulation will commence with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) and the dose will be adjusted according to the ovarian response. Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antagonist Group (Flexible protocol):</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ovarian stimulation in this group will be started with recombinant Follicle-Stimulating Hormone (r-FSH) or r-FSH + human Menopausal Gonadotropin (hMG) on the third day of the menstrual cycle and the dose will be adjusted according to the ovarian response. Initiation of 0.25 mg of GnRH antagonist; Cetrorelix; will take place after detecting a leading follicle diameter ≥ 14 mm. GnRH antagonist administration will be continued till the day of ovulation triggering, which will be accomplished by given 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm. After 35±2 hours of ovulation triggering, the oocytes will be retrieved by transvaginal ultrasound-guided follicle aspiration. Then they will be prepared to undergo an Intracytoplasmic Sperm Injection (ICSI).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin acetate</intervention_name>
    <description>0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.</description>
    <arm_group_label>Agonist Group (Long protocol):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetrorelix</intervention_name>
    <description>0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.</description>
    <arm_group_label>Antagonist Group (Flexible protocol):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin</intervention_name>
    <description>Dosage adjustment according to the ovarian response.</description>
    <arm_group_label>Agonist Group (Long protocol):</arm_group_label>
    <arm_group_label>Antagonist Group (Flexible protocol):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Chorionic Gonadotropin (hCG)</intervention_name>
    <description>Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.</description>
    <arm_group_label>Agonist Group (Long protocol):</arm_group_label>
    <arm_group_label>Antagonist Group (Flexible protocol):</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PCOS women diagnosed according to the Rotterdam criteria undergoing IVF/ICSI.&#xD;
&#xD;
          -  Age: 18-39 years.&#xD;
&#xD;
          -  Both ovaries present.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 40 years.&#xD;
&#xD;
          -  History of three or more previous IVF failures.&#xD;
&#xD;
          -  Patients with hormonal disorders like hyperprolactinemia, thyroid disorders.&#xD;
&#xD;
          -  Patients who previously undergo Unilateral Oophorectomy.&#xD;
&#xD;
          -  Patients with chronic diseases: diabetes mellitus, cardiovascular diseases, liver&#xD;
             diseases, kidney diseases.&#xD;
&#xD;
          -  Patients with diseases may affect IVF outcomes: Endometriosis, uterine fibroids,&#xD;
             Hydrosalpinx, Adenomyosis, autoimmune diseases,&#xD;
&#xD;
          -  Cancer.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sally Kadoura, B Pharm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Damascus University, Damascus, Syria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdul Hakim Nattouf, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Professor at Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Damascus University, Damascus, Syria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marwan Alhalabi, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Professor at Department of Embryology and Reproductive Medicine, Faculty of Medicine, Damascus University, Damascus, Syria.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sally Kadoura, B Pharm, MD</last_name>
    <phone>+963991995326</phone>
    <email>sally.kadoura@damascusuniversity.edu.sy</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abdul Hakim Nattouf, MD, PhD</last_name>
    <phone>+963933711846</phone>
    <email>abdulhakim.nattouf@damascusuniversity.edu.sy</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Orient Hospital</name>
      <address>
        <city>Damascus</city>
        <country>Syrian Arab Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marwan Alhalabi, MD, PhD</last_name>
      <phone>+963966400055</phone>
      <email>profalhalabi@icloud.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Syrian Arab Republic</country>
  </location_countries>
  <reference>
    <citation>Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, Lizneva D, Natterson-Horowtiz B, Teede HJ, Yildiz BO. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016 Aug 11;2:16057. doi: 10.1038/nrdp.2016.57. Review.</citation>
    <PMID>27510637</PMID>
  </reference>
  <reference>
    <citation>Dennett CC, Simon J. The role of polycystic ovary syndrome in reproductive and metabolic health: overview and approaches for treatment. Diabetes Spectr. 2015 May;28(2):116-20. doi: 10.2337/diaspect.28.2.116.</citation>
    <PMID>25987810</PMID>
  </reference>
  <reference>
    <citation>Lai Q, Zhang H, Zhu G, Li Y, Jin L, He L, Zhang Z, Yang P, Yu Q, Zhang S, Xu JF, Wang CY. Comparison of the GnRH agonist and antagonist protocol on the same patients in assisted reproduction during controlled ovarian stimulation cycles. Int J Clin Exp Pathol. 2013 Aug 15;6(9):1903-10. eCollection 2013.</citation>
    <PMID>24040457</PMID>
  </reference>
  <reference>
    <citation>Hoseini FS, Noori Mugahi SM, Akbari-Asbagh F, Eftekhari-Yazdi P, Aflatoonian B, Aghaee-Bakhtiari SH, Aflatoonian R, Salsabili N. A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression. Daru. 2014 Oct 7;22:67. doi: 10.1186/s40199-014-0067-4.</citation>
    <PMID>25288473</PMID>
  </reference>
  <reference>
    <citation>Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016 Apr 29;4:CD001750. doi: 10.1002/14651858.CD001750.pub4. Review.</citation>
    <PMID>27126581</PMID>
  </reference>
  <reference>
    <citation>Binder NK, Evans J, Salamonsen LA, Gardner DK, Kaitu'u-Lino TJ, Hannan NJ. Placental Growth Factor Is Secreted by the Human Endometrium and Has Potential Important Functions during Embryo Development and Implantation. PLoS One. 2016 Oct 6;11(10):e0163096. doi: 10.1371/journal.pone.0163096. eCollection 2016.</citation>
    <PMID>27711226</PMID>
  </reference>
  <reference>
    <citation>Bender HR, Trau HA, Duffy DM. Placental Growth Factor Is Required for Ovulation, Luteinization, and Angiogenesis in Primate Ovulatory Follicles. Endocrinology. 2018 Feb 1;159(2):710-722. doi: 10.1210/en.2017-00739.</citation>
    <PMID>29095972</PMID>
  </reference>
  <reference>
    <citation>Tal R, Seifer DB, Grazi RV, Malter HE. Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation. Reprod Biol Endocrinol. 2014 Aug 20;12:82. doi: 10.1186/1477-7827-12-82.</citation>
    <PMID>25141961</PMID>
  </reference>
  <reference>
    <citation>Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004 Jan;81(1):19-25.</citation>
    <PMID>14711538</PMID>
  </reference>
  <reference>
    <citation>Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod. 2011 Jun;26(6):1270-83. doi: 10.1093/humrep/der037. Epub 2011 Apr 18.</citation>
    <PMID>21502182</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GnRH Agonist</keyword>
  <keyword>GnRH Antagonist</keyword>
  <keyword>Assisted reproduction technique</keyword>
  <keyword>In Vitro Fertilization</keyword>
  <keyword>Intracytoplasmic sperm injection</keyword>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <keyword>Placental growth factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Cetrorelix</mesh_term>
    <mesh_term>Menotropins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

